Trial Profile
A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Amcasertib (Primary) ; Napabucasin (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America
- 17 Jul 2020 Status changed from active, no longer recruiting to completed.
- 26 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Nov 2019.
- 30 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.